These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 21187593

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Denosumab for treatment of postmenopausal osteoporosis].
    Syversen U, Halse JI, Geisler J, Eriksen EF.
    Tidsskr Nor Laegeforen; 2011 Oct 04; 131(19):1893-6. PubMed ID: 21984295
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
    Mera K, Ito K.
    Clin Calcium; 2007 Jan 04; 17(1):37-46. PubMed ID: 17211092
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
    Geusens P.
    Clin Interv Aging; 2009 Jan 04; 4():241-50. PubMed ID: 19554095
    [Abstract] [Full Text] [Related]

  • 12. Denosumab in postmenopausal women with low bone mineral density.
    McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group.
    N Engl J Med; 2006 Feb 23; 354(8):821-31. PubMed ID: 16495394
    [Abstract] [Full Text] [Related]

  • 13. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
    Tankó LB.
    Curr Opin Investig Drugs; 2007 Oct 23; 8(10):830-5. PubMed ID: 17907059
    [Abstract] [Full Text] [Related]

  • 14. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA, AMG 162 Bone Loss Study Group.
    J Bone Miner Res; 2007 Dec 23; 22(12):1832-41. PubMed ID: 17708711
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Denosumab: What's new?
    Bogado CE, Zanchetta MB, Boailchuk JA, Massari FE, Zanchetta JR.
    Curr Osteoporos Rep; 2011 Mar 23; 9(1):12-9. PubMed ID: 21132405
    [Abstract] [Full Text] [Related]

  • 17. Denosumab: anti-RANKL antibody.
    Miller PD.
    Curr Osteoporos Rep; 2009 Mar 23; 7(1):18-22. PubMed ID: 19239825
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Denosumab: an update.
    Bogado CE, Boailchuk JA, Zanchetta MB, Massari FE, Zanchetta JR.
    Drugs Today (Barc); 2011 Aug 23; 47(8):605-13. PubMed ID: 21850283
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.